pantoprazole has been researched along with Pyrosis in 24 studies
Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.
pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients." | 9.19 | Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. ( Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 9.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "To compare the efficacy and tolerability of S-pantoprazole (20 mg once a day) versus racemic pantoprazole (40 mg once a day) in the treatment of gastro-esophageal reflux disease (GERD)." | 9.12 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. ( Erram, SS; Mandora, VP; Pai, NV; Pai, VG; Shinde, JK; Thacker, HP, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 9.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "Esomeprazole 40 mg is more effective than pantoprazole 40 mg for healing EE and providing resolution of associated heartburn." | 9.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 9.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 9.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 8.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 7.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 6.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "The objective of this study was to assess the efficacy, safety, and tolerability of pantoprazole magnesium 40 mg once daily for 4 weeks, on the relief of reflux symptoms in gastroesophageal reflux disease (GERD) patients." | 5.19 | Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study. ( Mateos, G; Morales-Arámbula, M; Orozco-Gamiz, A; Remes-Troche, JM; Sobrino-Cossío, S; Soto-Pérez, JC; Tamayo de la Cuesta, JL; Teramoto-Matsubara, O, 2014) |
| "The use of esomeprazole rather than pantoprazole increases the probability of achieving resolution of heartburn during reflux oesophagitis-healing therapy." | 5.14 | Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009) |
| "The mean heartburn score in patients treated with esomeprazole more rapidly decreased than those receiving other PPI." | 5.14 | Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis. ( Zheng, RN, 2009) |
| "This post-hoc analysis used data from the maintenance phase of the EXPO study (AstraZeneca study code: SH-NEG-0008); 2766 patients with healed reflux oesophagitis and resolved heartburn received once-daily esomeprazole 20 mg or pantoprazole 20 mg for 6 months." | 5.14 | Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study. ( Armstrong, D; Eklund, S; Labenz, J; Leodolter, A; Zetterstrand, S, 2009) |
| "In GERD patients with nocturnal heartburn, rabeprazole 20 mg was significantly more effective than pantoprazole 40 mg in percentage time with intragastric pH >4 during the nighttime, daytime, and 24-h periods." | 5.14 | Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn. ( Delemos, B; Ieni, J; Lococo, J; Miner, P; Xiang, J, 2010) |
| "To compare the efficacy and tolerability of S-pantoprazole (20 mg once a day) versus racemic pantoprazole (40 mg once a day) in the treatment of gastro-esophageal reflux disease (GERD)." | 5.12 | Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease. ( Erram, SS; Mandora, VP; Pai, NV; Pai, VG; Shinde, JK; Thacker, HP, 2006) |
| "Rabeprazole and pantoprazole are both used for symptomatic treatment of gastro-oesophageal reflux disease (GERD)." | 5.12 | Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn. ( Baisley, K; Boyce, M; Delemos, B; Lee, D; Lomax, K; Morocutti, A; Warrington, S, 2007) |
| "Esomeprazole 40 mg is more effective than pantoprazole 40 mg for healing EE and providing resolution of associated heartburn." | 5.11 | A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. ( Armstrong, D; Eklund, S; Juergens, H; Katelaris, P; Keeling, N; Labenz, J; Lauritsen, K; Nauclér, E; Preiksaitis, H; Schmidt, S; Schütze, K; Wallner, G, 2005) |
| "To investigate whether pantoprazole (20 mg/d) produces significantly greater symptom control than ranitidine (300 mg/d) in patients with gastro-oesophageal reflux disease (GORD)." | 5.10 | Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. ( Katelaris, P; Moore, MG; Sprogis, A; Talley, NJ, 2002) |
| " Patients with GERD, characterized by heartburn that had occurred 4 or more times per week for at least 6 months, were treated for 28 days with either pantoprazole 40 mg once daily or nizatidine 150 mg twice daily." | 5.10 | Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine. ( Armstrong, D; Paré, P; Pericak, D; Pyzyk, M, 2003) |
| "In our study omeprazole was superior to either lansoprazole or pantoprazole in the maintenance treatment of complicated gastro-oesophageal reflux disease." | 5.08 | A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. ( Diehl, KL; Geyer, P; Jaspersen, D; Martens, E; Schoeppner, H, 1998) |
| "The standard-dose esomeprazole 40 mg had more superiority in mucosal erosion healing and heartburn relief." | 4.95 | Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis. ( Li, MJ; Li, Q; Liu, LQ; Sun, M, 2017) |
| "Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis." | 4.82 | Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. ( Bochenek, WJ; Fraga, PD; Mack, ME; Metz, DC, 2004) |
| "Patients with heartburn and negative endoscopy were treated with esomeprazole or pantoprazole 40 mg daily for 8 weeks." | 3.80 | Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. ( Antonelli, A; Bellini, M; de Bortoli, N; Frazzoni, M; Marchi, S; Martinucci, I; Piaggi, P; Savarino, E; Savarino, V, 2014) |
| " The aim of the present study was to assess the prevalence of heartburn and associated sleep complaints and the response to standard medical therapy with pantoprazole in primary and secondary care esophagitis patients in Belgium." | 3.77 | Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis. ( Imschoot, J; Kindt, S; Tack, J, 2011) |
| "In patients with nonerosive GERD there was no significant difference in symptomatic response to either regimen (17/20 in group A and 7/9 in group B responded; P = 0." | 2.71 | Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial. ( Ahuja, V; Kashyap, PC; Madan, K; Sharma, MP, 2004) |
| "Omeprazole was healthcare professional (HCP)-preferred first-line treatment (60." | 1.72 | Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients. ( Atkinson, C; Brunton, S; Howden, CW; Jacob, R; Mark Fendrick, A; Pelletier, C; Spechler, SJ; Vaezi, MF, 2022) |
| "Dysphagia was assessed prior to treatment, at 6 months of medical therapy, and at 6 months after surgery." | 1.30 | The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture. ( Gadenstaetter, M; Glaser, K; Hinder, RA; Profanter, C; Wetscher, GJ, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (8.33) | 18.2507 |
| 2000's | 14 (58.33) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 1 (4.17) | 2.80 |
| Authors | Studies |
|---|---|
| Vaezi, MF | 1 |
| Brunton, S | 1 |
| Mark Fendrick, A | 1 |
| Howden, CW | 1 |
| Atkinson, C | 1 |
| Pelletier, C | 1 |
| Jacob, R | 1 |
| Spechler, SJ | 1 |
| Li, MJ | 1 |
| Li, Q | 1 |
| Sun, M | 1 |
| Liu, LQ | 1 |
| Remes-Troche, JM | 1 |
| Sobrino-Cossío, S | 1 |
| Soto-Pérez, JC | 1 |
| Teramoto-Matsubara, O | 1 |
| Morales-Arámbula, M | 1 |
| Orozco-Gamiz, A | 1 |
| Tamayo de la Cuesta, JL | 1 |
| Mateos, G | 1 |
| Martinucci, I | 1 |
| de Bortoli, N | 1 |
| Savarino, E | 1 |
| Piaggi, P | 1 |
| Bellini, M | 1 |
| Antonelli, A | 1 |
| Savarino, V | 1 |
| Frazzoni, M | 1 |
| Marchi, S | 1 |
| Becker, V | 1 |
| Grotz, S | 1 |
| Schlag, C | 1 |
| Nennstiel, S | 1 |
| Beitz, A | 1 |
| Haller, B | 1 |
| Schmid, RM | 1 |
| Meining, A | 1 |
| Bajbouj, M | 1 |
| Labenz, J | 3 |
| Armstrong, D | 4 |
| Zetterstrand, S | 2 |
| Eklund, S | 3 |
| Leodolter, A | 2 |
| Zheng, RN | 1 |
| Miner, P | 1 |
| Delemos, B | 2 |
| Xiang, J | 1 |
| Lococo, J | 1 |
| Ieni, J | 1 |
| Kindt, S | 1 |
| Imschoot, J | 1 |
| Tack, J | 1 |
| Musikatavorn, K | 1 |
| Tansangngam, P | 1 |
| Lumlertgul, S | 1 |
| Komindr, A | 1 |
| Talley, NJ | 1 |
| Moore, MG | 1 |
| Sprogis, A | 1 |
| Katelaris, P | 2 |
| Paré, P | 1 |
| Pericak, D | 1 |
| Pyzyk, M | 1 |
| Bochenek, WJ | 1 |
| Mack, ME | 1 |
| Fraga, PD | 1 |
| Metz, DC | 1 |
| Madan, K | 1 |
| Ahuja, V | 1 |
| Kashyap, PC | 1 |
| Sharma, MP | 1 |
| Lauritsen, K | 1 |
| Schmidt, S | 1 |
| Schütze, K | 1 |
| Wallner, G | 1 |
| Juergens, H | 1 |
| Preiksaitis, H | 1 |
| Keeling, N | 1 |
| Nauclér, E | 1 |
| Calleja, JL | 1 |
| Suarez, M | 1 |
| De Tejada, AH | 1 |
| Navarro, A | 1 |
| Pai, VG | 1 |
| Pai, NV | 1 |
| Thacker, HP | 1 |
| Shinde, JK | 1 |
| Mandora, VP | 1 |
| Erram, SS | 1 |
| Warrington, S | 1 |
| Baisley, K | 1 |
| Lee, D | 1 |
| Lomax, K | 1 |
| Boyce, M | 1 |
| Morocutti, A | 1 |
| Jaspersen, D | 1 |
| Diehl, KL | 1 |
| Schoeppner, H | 1 |
| Geyer, P | 1 |
| Martens, E | 1 |
| Wetscher, GJ | 1 |
| Glaser, K | 1 |
| Gadenstaetter, M | 1 |
| Profanter, C | 1 |
| Hinder, RA | 1 |
| Dupas, JL | 1 |
| Houcke, P | 1 |
| Samoyeau, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Two-way Crossover Study of the Effects of a Single Dose of Rabeprazole or Pantoprazole on 24-hour Intragastric Acidity and Esophageal Acid Exposure in GERD Patients With a History of Nocturnal Heartburn[NCT00237367] | Phase 4 | 52 participants (Actual) | Interventional | Completed | |||
| A Randomized, Controlled Trial of Adding Intravenous Pantoprazole to Conventional Treatment for the Immediate Relief of Dyspeptic Pain[NCT01281501] | Phase 4 | 87 participants (Actual) | Interventional | 2011-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Non-responders defined the participants who had < 50% decrease in post-treatment VAS compared with pre-treatment evaluation or post-treatment scores > 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 8 |
| Pantoprazole | 11 |
"Responders define the participants who have ≥ 50% decrease in post-treatment pain scores compared with the pre-treatment evaluation and also have the post-treatment scores ≤ 40 at the end of the study." (NCT01281501)
Timeframe: pretreatment and 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 36 |
| Pantoprazole | 32 |
The satisfaction will be assessed by a simple, self-reported yes/no question. (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | participants (Number) |
|---|---|
| Conventional | 34 |
| Pantoprazole | 34 |
"Post-treatment VAS will be consecutively measured every 15 minutes until 1 hour after treatment. Minimal and maximal VAS score of every measurement is 0 to 100 millimeters. VAS scores at 1 hour after treatment were the primary outcome measurement. The patients who had <50% decrement between pre- and 1-hour post-treatment VAS or post-treatment scores > 40 millimeters were defined as Non-responders(worse outcome). In the same way, those who had ≥ 50% decrement between pre- and 1-hour post-treatment VAS and post-treatment scores≤ 40 millimeters were defined as Responders (good outcome)." (NCT01281501)
Timeframe: 1 hour after treatment
| Intervention | millimeter (Mean) |
|---|---|
| Conventional | 17 |
| Pantoprazole | 19 |
2 reviews available for pantoprazole and Pyrosis
| Article | Year |
|---|---|
Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis: A PRISMA-compliant network meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Comparative Effectiveness Research; Dexlansoprazole; | 2017 |
Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Benzimidazoles; D | 2004 |
14 trials available for pantoprazole and Pyrosis
| Article | Year |
|---|---|
Efficacy, safety, and tolerability of pantoprazole magnesium in the treatment of reflux symptoms in patients with gastroesophageal reflux disease (GERD): a prospective, multicenter, post-marketing observational study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Female; Gastroesophageal Reflux; | 2014 |
Clinical trial: factors associated with resolution of heartburn in patients with reflux oesophagitis--results from the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; An | 2009 |
Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Esomeprazole; Female; Gastr | 2009 |
Clinical trial: factors associated with freedom from relapse of heartburn in patients with healed reflux oesophagitis--results from the maintenance phase of the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Dose-Res | 2009 |
Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2010 |
A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute Pain; Adult; Anti-Ulcer Agents; Double-Blind Method; | 2012 |
Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 2002 |
Pantoprazole rapidly improves health-related quality of life in patients with heartburn: a prospective, randomized, double blind comparative study with nizatidine.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2003 |
Comparison of efficacy of pantoprazole alone versus pantoprazole plus mosapride in therapy of gastroesophageal reflux disease: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agen | 2004 |
A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2005 |
Comparative clinical trial of S-pantoprazole versus racemic pantoprazole in the treatment of gastro-esophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Dose-Response R | 2006 |
Pharmacodynamic effects of single doses of rabeprazole 20 mg and pantoprazole 40 mg in patients with GERD and nocturnal heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Ulcer Agents; Cross-Over Stud | 2007 |
A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Deglutition | 1998 |
Pantoprazole versus lansoprazole in French patients with reflux esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Benzimidazoles; Double-Blind Meth | 2001 |
8 other studies available for pantoprazole and Pyrosis
| Article | Year |
|---|---|
Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Esophagitis; Gastroesoph | 2022 |
Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Electric Impedance; Esomeprazole; Esophageal pH Monitoring; | 2014 |
Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Electric Impedance; Esophageal pH Monitoring; | 2014 |
Prevalence of and impact of pantoprazole on nocturnal heartburn and associated sleep complaints in patients with erosive esophagitis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Alcoholism; Anorexia; Anti-Inflammatory Agents | 2011 |
[The proton pump especially steady in grip. Fast help for nightly reflux complaints].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Heartburn; Humans; Omepr | 2003 |
[When sour does not make merry at all . Fast relief for patients with reflux].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Enzyme Inhibitors; Gastr | 2003 |
Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Benzimidazoles; Case-Control Studies; Chi-Squa | 2005 |
The effect of medical therapy and antireflux surgery on dysphagia in patients with gastroesophageal reflux disease without esophageal stricture.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Ulcer Agents; Benzimidazoles; Cisapride; | 1999 |